Patients treated with tyrosine kinase inhibitors received olanzapine to address adverse effects including nausea/vomiting, anorexia, insomnia, and weight loss.

A Chinese study, led by Arnold ASH Chee, AFCOphthHK, found that a tyrosine kinase inhibitor achieved both durable disease control and visual improvement in patients with epidermal growth factor ...

No writing assistance was utilized in the production of this manuscript. Tyrosine kinase inhibitors (TKIs) are used for the targeted treatment of cancer. TKIs produce a range of serious adverse ...

GU ASCO annual meeting featured a kidney cancer session and a presentation by Dr. Michael Staehler discussing 18 F-PSMA-1007 PET/CT for response assessment in patients with metastatic renal cell ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

Glycolytic inhibitors significantly enhances the cytotoxicity induced by FLT3 tyrosine kinase inhibitor sorafenib. Importantly, such combination provides substantial therapeutic benefit in a ...

Laboratory of Protein Engineering and Bioinformatics (PROTEP), Department of Biochemistry, Faculty of Science, Kasetsart University, Bangkok 10900, Thailand Department of Clinical Chemistry, Faculty ...

Background: This study examines the risks of hypertension and thrombotic events in NSCLC patients treated with Tyrosine Kinase Inhibitors (TKIs). Objective: To compare the safety profiles of TKIs used ...

Panelists discuss how data from Mansour and colleagues suggesting potential Bruton tyrosine kinase (BTK) inhibitor ...

Panelists discuss how successful transitions between Bruton tyrosine kinase (BTK) inhibitors require careful management of ...

Arcus Biosciences (RCUS) presented new data for casdatifan, a HIF-2a inhibitor with best-in-class potential, in an oral plenary session by Dr.